JP2004511527A5 - - Google Patents

Info

Publication number

JP2004511527A5

JP2004511527A5 JP2002535687A JP2002535687A JP2004511527A5 JP 2004511527 A5 JP2004511527 A5 JP 2004511527A5 JP 2002535687 A JP2002535687 A JP 2002535687A JP 2002535687 A JP2002535687 A JP 2002535687A JP 2004511527 A5 JP2004511527 A5 JP 2004511527A5

Authority

JP

Japan

Prior art keywords

antigen

composition according

neu

fusion partner

heterologous fusion

Prior art date

2001-10-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 30
• 239000000427 antigen Substances 0.000 claims description 26
• 102000036639 antigens Human genes 0.000 claims description 26
• 108091007433 antigens Proteins 0.000 claims description 26
• 230000004927 fusion Effects 0.000 claims description 18
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 16
• 206010028980 Neoplasm Diseases 0.000 claims description 14
• 229930182490 saponin Natural products 0.000 claims description 12
• 150000007949 saponins Chemical class 0.000 claims description 12
• 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 11
• 201000011510 cancer Diseases 0.000 claims description 10
• 102100034872 Kallikrein-4 Human genes 0.000 claims description 8
• 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 8
• 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 8
• 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims description 8
• 108091034117 Oligonucleotide Proteins 0.000 claims description 8
• 230000003308 immunostimulating effect Effects 0.000 claims description 8
• 108010024383 kallikrein 4 Proteins 0.000 claims description 8
• 150000001413 amino acids Chemical class 0.000 claims description 6
• 239000012634 fragment Substances 0.000 claims description 6
• 230000002163 immunogen Effects 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 4
• 239000002158 endotoxin Substances 0.000 claims description 4
• 229920006008 lipopolysaccharide Polymers 0.000 claims description 4
• 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 2
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 2
• 239000002502 liposome Substances 0.000 claims description 2
• 238000012737 microarray-based gene expression Methods 0.000 claims description 2
• 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
• 239000007764 o/w emulsion Substances 0.000 claims description 2
• 230000026731 phosphorylation Effects 0.000 claims description 2
• 238000006366 phosphorylation reaction Methods 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 235000017709 saponins Nutrition 0.000 claims 6
• 101150029707 ERBB2 gene Proteins 0.000 claims 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1